Viewpoint Molecular Targeting® Partners with Industry Leader Pepscan to Accelerate Peptide Discovery Program

Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into a collaborative partnership with Netherlands-based Pepscan Therapeutics B.V. (“Pepscan”), the all-in-one peptide service provider with proprietary peptide constraining technologies.

“Pepscan is clearly a world leader in peptide discovery and lead optimization, and we are delighted to have taken the first step on this journey,” commented Michael K Schultz PhD, Chief Science Officer and Co-Founder of Viewpoint. “In our diligence, the Pepscan team is technically and professionally the strongest we’ve had the pleasure to work with. We are particularly excited to see how their CLIPS™ innovative scaffold technology results in superior synthetic peptide candidates for us to develop.”

Read further